

Technology Transfer on or before August 31, 2016 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated Start-Up Exclusive Evaluation Option License Agreement should be directed to: Surekha Vathyam, Ph.D., Senior Licensing and Patenting Manager, National Cancer Institute Technology Transfer Center, 9609 Medical Center Drive, Rm 1E-530 MSC9702, Rockville, MD 20850-9702, Email: [vathyams@mail.nih.gov](mailto:vathyams@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The subject technology describes methods of using derivative compositions of hydroxylamine, including N-t-butyl hydroxylamine (NtBuHA), for the treatment of thioesterase deficiencies. NtBuHA is small molecule derivative of hydroxylamine which possesses strong anti-oxidant properties and an ability to cleave thioester linkages with high specificity. These capabilities suggest that NtBuHA may be useful as a modulator of intracellular protein palmitoylation dynamics when endogenous mechanisms are insufficient to support normal function.

The compounds disclosed in this invention have potential therapeutic applications for both the management of diseases driven by excess accumulation or malfunction of palmitoylated proteins. Target disorders may therefore include neuronal ceroid lipofuscinoses (also known as Batten Disease), amyotrophic lateral sclerosis, and Ras-driven cancers.

The prospective Start-Up Exclusive Evaluation Option License Agreement is being considered under the small business initiative launched on October 1, 2011 and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective Start-Up Exclusive Evaluation Option License Agreement may be granted unless the NIH receives written evidence and argument that establishes that the grant of the contemplated Start-Up Exclusive Evaluation Option License Agreement would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7 within fifteen (15) days from the date of this published notice.

Complete applications for a license in an appropriate field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Start-Up Exclusive Evaluation Option License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released

under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 8, 2016.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-19418 Filed 8-15-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Integrating Biospecimen Science Approaches into Clinical Assay Development.

*Date:* September 8, 2016.

*Time:* 11:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W108, Rockville, MD 20892-9750, 240-276-6343, [schweinfestcw@mail.nih.gov](mailto:schweinfestcw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Program Project I SEP-1.

*Date:* September 29-30, 2016.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Blvd., Gaithersburg, MD 20878.

*Contact Person:* Shakeel Ahmad, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W122, Rockville, MD 20892-9750, 240-276-6349, [ahmads@mail.nih.gov](mailto:ahmads@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Barrett's Esophagus Translational Research Network Review.

*Date:* October 20, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Wlodek Lopaczynski, MD, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W608, Rockville, MD 20892-9750, 240-276-6458, [lopacw@mail.nih.gov](mailto:lopacw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; PAR 15-266 Imaging.

*Date:* October 24, 2016.

*Time:* 11:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W030, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Kenneth L. Bielat, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W244, Rockville, MD 20892-9750, 240-276-6373, [bielatk@mail.nih.gov](mailto:bielatk@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Omnibus R03 SEP-3.

*Date:* November 3, 2016.

*Time:* 8:00 a.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

*Contact Person:* Byeong-Chel C. Lee, Ph.D., Scientific Review Officer, Review Training and Resources Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W238, Rockville, MD 20892-9750, 240-276-6260, [byeong-chel.lee@nih.gov](mailto:byeong-chel.lee@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Pancreatic Cancer Detection Consortium (U01).

*Date:* November 9, 2016.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W032, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W120, Rockville, MD 20892-9750, 240-276-6457, [mh101v@nih.gov](mailto:mh101v@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Biospecimen Science.

*Date:* December 9, 2016.

*Time:* 10:00 a.m. to 3:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Rockville, MD 20850, (Telephone Conference Call).

**Contact Person:** Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W260, Rockville, MD 20892-9750, 240-276-5856, [nadeem.khan@nih.gov](mailto:nadeem.khan@nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 10, 2016.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-19416 Filed 8-15-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

**ADDRESSES:** Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.

#### FOR FURTHER INFORMATION CONTACT:

Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or

Email [ncitechtransfer@mail.nih.gov](mailto:ncitechtransfer@mail.nih.gov). A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** Technology description follows.

**Title of invention:** Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.

**Keywords:** Glypican-2, GPC2, Antibody, Immunotoxin, Recombinant Immunotoxin, RIT, Chimeric Antigen Receptor, CAR, Antibody-drug Conjugate, ADC, bispecific antibody, neuroblastoma.

**Description of Technology:** Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This demonstrates a need for more effective therapies.

Glypican-2 (GPC2) is a cell surface protein that has been shown to be preferentially expressed on numerous pediatric cancers, including neuroblastoma. Due to this preferential expression, GPC2 represents a potential candidate for targeted therapy. Researchers at the National Cancer Institute's Laboratory of Molecular Biology (NCI LMB) have developed and isolated several single domain monoclonal human antibodies against GPC2. This technology covers the naked GPC2 antibodies as well as their use as targeting domains in recombinant immunotoxins (RITs) and chimeric antigen receptors (CARs). RITs (using clones LH1, LH4, or LH7) and CARs (using LH7) have shown specific killing activity against GPC2-expressing cells, suggesting that these candidates may be further developed as therapeutics.

The technology has been validated with *in-vitro* studies (human anti-GPC2 RITs and CARs can bind to, and kill, GPC2-positive tumor cells) and the researchers are currently developing mouse models to further develop GPC2-targeted therapies.

#### Potential Commercial Applications:

- Therapeutic applications include: Unconjugated antibodies, and use as targeting moieties for immunoconjugates such as CARs, ADCs, immunotoxins, and bispecific antibodies
- Diagnostic agent for detecting and monitoring target-expressing malignancies

#### Value Proposition:

- First to market potential—No current clinical trials with GPC2-targeted therapies
- Human antibody with high specificity and binding to targets results in less non-specific cell killing, therefore fewer potential side-effects for the patient
- Small size of single domain antibodies enhances stability, solubility, and target recognition
- Development Stage:** *In-vitro*.
- Inventor(s):** Mitchell Ho (NCI), *et al*.
- Intellectual Property:** US Provisional Application 62/369,861 (HHS Reference No. E-211-2016/0-US-01) filed August 2, 2016, entitled "Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma."

#### Collaboration Opportunity:

Researchers at the NCI seek parties interested in licensing or co-developing GPC2 antibodies and/or conjugates.

**Contact Information:** Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: [john.hewes@nih.gov](mailto:john.hewes@nih.gov).

Dated: August 8, 2016.

**John D. Hewes,**

*Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-19419 Filed 8-15-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Advisory Committee for Women's Services; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration's (SAMHSA) Advisory Committee for Women's Services (ACWS) on August 24, 2016.

The meeting will include discussions on child welfare and substance use disorders among families; improving the health of women and girls; recovery-oriented systems of care and what they mean for women; accountable health communities and how they relate to behavioral health; and a conversation with the SAMHSA Deputy of Operations and the Chief of Staff.

The meeting is open to the public and will be held at SAMHSA, 5600 Fishers Lane, Rockville, MD 20857, in Conference Room 5N76. Attendance by the public will be limited to space available. Interested persons may